comparemela.com

Latest Breaking News On - Biocryst pharmaceuticals inc - Page 15 : comparemela.com

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

BioCryst to Present at 42nd Annual J P Morgan Healthcare Conference - BioCryst Pharma (NASDAQ:BCRX)

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San

BioCryst to Present at 42nd Annual J P Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 BioCryst Pharmaceuticals, Inc. today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on.

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Receives Average Rating of Buy from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.